Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for high-risk neuroblastoma
Background Treatment for children with high-risk neuroblastoma relies on conventional chemotherapy and anti-GD2 immunotherapy. However, 5-year survival is only 50%, with high rates of late effects. Targeted therapy combinations are a major priority for these patients. The BCL2 inhibitor venetoclax, in combination with cyclophosphamide/topotecan, has clinical activity in relapsed and refractory neuroblastoma. We sought more effective and safer venetoclax combinations through systematic preclinical testing. Methods Synergistic combinations were identified by high-throughput screening using patient-derived xenograft (PDX) models and confirmed in vivo. The leading combination (venetoclax-alisertib) was compared to combination chemotherapy in a clinical trial-like study using 22 PDX models, in scheduling experiments designed to reduce short-term toxicity, and in combination with anti-GD2 immunotherapy. BCL2 and Bim-BCL2 complex protein levels were assessed as predictors of sensitivity. Results In vitro synergy with venetoclax was observed for standard-of-care chemotherapies and targeted agents, including DNA topoisomerase, microtubule, HDAC and Aurora kinase A (AURKA) inhibitors. Venetoclax-alisertib was particularly effective in vivo. In an n = 1 study, venetoclax-alisertib induced objective response in all models. Activity was most striking in models of MYCN -amplified disease ( n = 12), doubling median survival time compared to cyclophosphamide/topotecan, and outperforming venetoclax-cyclophosphamide-topotecan. Efficacy was maintained with discontinuous schedules, minimizing hematological toxicity without substantially compromising activity. Venetoclax-alisertib was strikingly effective with anti-GD2 immunotherapy, allowing long-term survival of PDX-engrafted animals. BCL2 expression and BCL2-Bim complex levels were of limited value for predicting response. Conclusions Our findings support advancement of BCL2-AURKA inhibition to clinical trial for high-risk neuroblastoma with or without anti-GD2 immunotherapy, particularly in patients with MYCN -amplified disease.
Authors
- Angela Lin (ORCID: https://orcid.org/0000-0002-2637-3070)
- Alvin Kamili (ORCID: https://orcid.org/0000-0002-4864-1195)
- Murray D. Norris (ORCID: https://orcid.org/0000-0002-0632-4589)
- Roxanne Cadiz (ORCID: https://orcid.org/0009-0004-6768-8601)
- Toby N. Trahair (ORCID: https://orcid.org/0000-0002-3295-228X)
- Caroline J. Atkinson (ORCID: https://orcid.org/0000-0001-7693-1213)
- M. Emmy M. Dolman (ORCID: https://orcid.org/0000-0002-0567-5918)
- Marie Wong (ORCID: https://orcid.org/0000-0003-0066-6606)
- Chelsea Mayoh (ORCID: https://orcid.org/0000-0002-6398-3046)
- Andrew J. Gifford (ORCID: https://orcid.org/0000-0002-4092-2347)
- Michelle Haber (ORCID: https://orcid.org/0000-0003-2036-8817)
- Lujing Cui (ORCID: https://orcid.org/0000-0003-4762-3099)
- Madeleine S. Wheatley (ORCID: https://orcid.org/0000-0002-0305-7999)
- Jamie I. Fletcher (ORCID: https://orcid.org/0000-0003-2949-9469)
- Greg M. Arndt (ORCID: https://orcid.org/0000-0003-3734-6171)
- Jayne E. Murray (ORCID: https://orcid.org/0000-0002-1861-6570)
- Timothy W. Failes (ORCID: https://orcid.org/0000-0003-4618-1057)
- Christina H.T. Bui
- Brandon A. Hearn (ORCID: https://orcid.org/0009-0002-1843-4774)
- Lewis Crowley (ORCID: https://orcid.org/0009-0004-9544-1681)
- Sadia Qureshi
- Isabella Temelkoska
- Leith-Justin Elhassadi
- Joan Solomon
Institutions
- UNSW Sydney (AU)
- Prince of Wales Hospital (AU)
- Children's Cancer Institute Australia (AU)
- Princess Máxima Center (NL)
- NSW Health Pathology (AU)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s13046-026-03875-4
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of New South Wales
- National Health and Medical Research Council